Data readout for SIM0505/CDH6 ADC Phase 1 dose escalation study and initiation of dose optimization in ovarian cancer are both anticipated in Q2 ...

In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, offers an overview of pivekimab sunirine and CD123-directed antibody-drug conjugates (ADCs) in the BPDCN pipeline.

Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...

New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026IM-1021 Phase 1 ongoing with initial data expected in 2026Three IND submissions for solid ...

Acquisition will create a U.S.- and China-based fully integrated biopharmaceutical company with revenue-producing commercial assets and a robust ...

Telix reported FY2025 revenue of $804M, up 56% YoY, with Precision Portfolio products Illuccix and Gozellix contributing $622M. Read why TLX stock is a Buy.

ALX Oncology pivots to targeting HER2-positive underperformance in the intent-to-treat gastric cancer population. See why ...

Researchers found that autistic and non-autistic people move their faces differently when expressing emotions like anger, happiness, and sadness. Autistic participants tended to rely on different ...

In January 2026, ALX Oncology announced topline data from the exploratory analysis conducted to identify biomarkers of response to the evorpacept/zanidatamab combination. These findings show that ...